Infinity Pharmaceuticals Competitors and Similar CompaniesClear all
Infinity Pharmaceuticals's competitors and similar companies include OncoStem Diagnostics, GlycoMimetics, Iovance Biotherapeutics and Kyowa Kirin.
 Infinity Pharmaceuticals Infinity Pharmaceuticals engages in the discovery and development of medicines for the treatment of cancer and related conditions. |  OncoStem Diagnostics OncoStem Diagnostics is a diagnostic oncology company focused on discovering and developing novel tests for improved treatment planning. |  GlycoMimetics GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers. |  Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. |  Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | |
Founding Date | Founding Date 2000 | Founding Date 2011 | Founding Date 2003 | Founding Date 2013 | Founding Date 2008 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Bengaluru, IN HQ | Locations Rockville, US HQ | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US | |
Employees | Employees 25 | Employees 24 | Employees 5025% increase | Employees 14868% increase | Employees 5,669 |
Valuation ($) | Valuation ($) 726.1 k | Valuation ($) N/A | Valuation ($) 31.6 m | Valuation ($) 3.3 b | Valuation ($) 8.8 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $2.6m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $10.8m (FY, 2025) | Revenue (est.) $263.5m (FY, 2025) | Revenue (est.) ¥496.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $173.2m (FY, 2025) | Cost of goods ¥114.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $90.3m (FY, 2025) | Gross profit ¥383.4b (FY, 2025) |
Net income | Net income ($44.4m) (FY, 2022) | Net income N/A | Net income ($153.9m) (FY, 2025) | Net income N/A | Net income ¥67b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 106.6m | Total funding raised $ 7m | Total funding raised $ 101.8m | Total funding raised $ 100m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
OncoStem Diagnostics
HQ
Bengaluru, IN
Employees
24
OncoStem Diagnostics is a diagnostic oncology company focused on discovering and developing novel tests for improved treatment planning.
View companyGlycoMimetics
HQ
Rockville, US
Employees
50↑ 25% increase
GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
View companyIovance Biotherapeutics
HQ
San Carlos, US
Employees
148
Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,669
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company